Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q3 2015 · 10-Q
Revenue$27.72M$27.72M+4,797.0% vs Q3 2014 Net Income-$36.02M-$36.02MN/M vs Q3 2014 EPS Diluted-$0.35-$0.35N/M vs Q3 2014 Operating Income-$34,933,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$35,235,000N/M Margins · derivedOperating margin-126.0%+5824.0 pt vs Q3 2014
Net margin-129.9%+6103.6 pt vs Q3 2014
ended Sep 30, 2016 · filed Nov 7, 2016 · 38 d after period end